Gabriela Guerron-Gomez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Gabriela Guerron-Gomez has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Eduardo Tuta-Quintero
School of Medicine, Universidad de la Sabana, Chia, Colombia
3 shared publications - Adriana Rojas-Villarraga
Research Institute, Fundación Universitaria de Ciencias de la salud, Bogotá, Colombia
1 shared publication - Alejandra Lozano-Forero
School of Medicine, Universidad de la Sabana, Chia, Colombia
1 shared publication - Alirio Rodrigo Bastidas Goyes
School of Medicine, Universidad de la Sabana, Chia, Colombia
1 shared publication Andres Mosquera-Zamudio
Research Institute, Fundación Universitaria de Ciencias de la Salud (FUCS), Bogotá, Colombia
1 shared publication- Angie Sandoval-Blanco
School of Medicine, Universidad de La Sabana, Campus del Puente del Común, Km. 7, Autopista Norte de Bogotá, Chía 250001, Colombia
1 shared publication
Latest Publications
- Open Access
- 15 September 2026
- Published by MDPI AG in Infectious Disease Reports
- Vol. 18 (5) , 103
Performance and Validation of a New Long-Term Mortality Risk Score in Community-Acquired Pneumonia: A Colombian Cohort
Background: Community-acquired pneumonia (CAP) causes significant long-term morbidity and mortality. Existing clinical scores focus on short-term outcomes, highlighting the need to validate tools that accurately predict 12-month mortality in hospitalized patients. Materials and Methods: A retrospective cohort of adults hospitalized with CAP from 2012 to 2020 was analyzed. Clinical, laboratory, radiological, and hospitalization-related data were collected. A Cox proportional hazards model was developed to predict post-acute mortality between 30 days and 12 months after hospital admission among patients with CAP who survived the first 30 days, with the cohort split 50:50. Model performance was evaluated using Area Under the Receiver Operating Characteristic Curve (AUROC) and standard diagnostic accuracy metrics. Results: A total of 13,851 patients with CAP were included. In the derivation cohort, independent predictors were altered mental status (HR 2.08; 95% CI 1.49–2.90; p < 0.05), elevated BUN (>30 mg/dL; HR 1.98; 95% CI 1.48–2.63; p < 0.05), temperature extremes (39.9 °C; HR 1.98; 95% CI 1.43–2.74; p < 0.05), corticosteroid use (HR 1.85; 95% CI 1.40–2.44; p < 0.05), neoplasia (HR 1.58; 95% CI 1.08–2.32; p < 0.05), and hospital stays longer than 8 days (HR 1.39; 95% CI 1.06–1.82; p < 0.05). The new score achieved the highest AUROC (0.69; 95% CI: 0.66–0.73), followed by PSI (0.65; 95% CI: 0.62–0.69), CURB-65 (0.63; 95% CI: 0.59–0.67), and CAPSI (0.62; 95% CI: 0.58–0.67). The optimal cutoff point for the new score was 3, as determined by the Youden index (0.339). The model sensitivity was 83.0%, specificity: 50.9%, PPV: 8.9%, and NPV: 99.0%. The LR+ was 1.69 (95% CI: 1.38–2.06), and the LR− was 0.33 (95% CI: 0.27–0.41). Conclusions: The new score demonstrated weak-to-moderate discriminatory capacity. The variables included in the new score reflect multiorgan involvement, disease severity, and comorbidity burden, all of which are associated with long-term mortality.
- 15 September 2026
- Published by MDPI AG in Infectious Disease Reports
- Vol. 18 (5) , 103
Open AccessPerformance and Validation of a New Long-Term Mortality Risk Score in Community-Acquired Pneumonia: A Colombian Cohort
Background: Community-acquired pneumonia (CAP) causes significant long-term morbidity and mortality. Existing clinical scores focus on short-term outcomes, highlighting the need to validate tools that accurately predict 12-month mortality in hospitalized patients. Materials and Methods: A retrospective cohort of adults hospitalized with CAP from 2012 to 2020 was analyzed. Clinical, laboratory, radiological, and hospitalization-related data were collected. A Cox proportional hazards model was developed to predict post-acute mortality between 30 days and 12 months after hospital admission among patients with CAP who survived the first 30 days, with the cohort split 50:50. Model performance was evaluated using Area Under the Receiver Operating Characteristic Curve (AUROC) and standard diagnostic accuracy metrics. Results: A total of 13,851 patients with CAP were included. In the derivation cohort, independent predictors were altered mental status (HR 2.08; 95% CI 1.49–2.90; p < 0.05), elevated BUN (>30 mg/dL; HR 1.98; 95% CI 1.48–2.63; p < 0.05), temperature extremes (39.9 °C; HR 1.98; 95% CI 1.43–2.74; p < 0.05), corticosteroid use (HR 1.85; 95% CI 1.40–2.44; p < 0.05), neoplasia (HR 1.58; 95% CI 1.08–2.32; p < 0.05), and hospital stays longer than 8 days (HR 1.39; 95% CI 1.06–1.82; p < 0.05). The new score achieved the highest AUROC (0.69; 95% CI: 0.66–0.73), followed by PSI (0.65; 95% CI: 0.62–0.69), CURB-65 (0.63; 95% CI: 0.59–0.67), and CAPSI (0.62; 95% CI: 0.58–0.67). The optimal cutoff point for the new score was 3, as determined by the Youden index (0.339). The model sensitivity was 83.0%, specificity: 50.9%, PPV: 8.9%, and NPV: 99.0%. The LR+ was 1.69 (95% CI: 1.38–2.06), and the LR− was 0.33 (95% CI: 0.27–0.41). Conclusions: The new score demonstrated weak-to-moderate discriminatory capacity. The variables included in the new score reflect multiorgan involvement, disease severity, and comorbidity burden, all of which are associated with long-term mortality.
- Open Access
- 17 August 2026
- Published by Elsevier in SSRN Electronic Journal
Implementation of an Integrated Electronic Health Record and Real-Time Dashboard System to Support Clinical Decision-Making in a Colombian Rheumatology Service
Background: Rheumatic diseases affect 10–20% of the global population and are a leading cause of disability. In Colombia, a limited rheumatology workforce and fragmented data systems hinder disease-burden monitoring, clinical decision-making, and resource planning. Electronic health records (EHR) integrated with real-time dashboards offer a scalable solution, yet their implementation in low- and middle-income countries (LMICs) remains scarce and underreported.Methods: We conducted a retrospective descriptive implementation study at the Rheumatology Department of Hospital de San José, Bogotá. Three data sources were integrated: administrative billing records, clinical EHR governed by Colombian Law 2015 of 2020, and a prospective REDCap research registry. Data from January 2020 to December 2023 underwent structured cleaning, deduplication, and consolidation into Google Sheets. SQL queries generated real-time visualizations through Looker Studio, enabling automated reporting of consultation volumes, demographics, ICD-10 diagnoses, and comorbidities. Implementation followed a multi-phase workflow with a multidisciplinary team of rheumatologists, epidemiologists, and data analysts.Findings: The dashboard captured 8,496 consultations from 4,698 unique patients over four years. Annual volumes rose from 1,130 in 2020 to a peak of 2,917 in 2022 (158% growth), declining slightly to 2,570 in 2023. Rheumatoid arthritis was the leading diagnosis (15.6%), followed by osteoarthritis (14.6%), fibromyalgia (11.8%), systemic lupus erythematosus (10.4%), Sjögren's syndrome (9.8%), and systemic sclerosis (4.7%), together accounting for 66.9% of diagnoses. Female patients comprised 82.3% of the cohort; polyautoimmunity was identified in 1.4%. The system reduced data fragmentation and enabled systematic longitudinal monitoring for the first time in this institution.Interpretation: Integrating freely available tools (REDCap and Looker Studio) can establish a functional, low-cost health information system in a resource-constrained LMIC setting. The resulting dashboard supported epidemiological monitoring for clinical management, resource planning, and research, and is scalable and replicable across rheumatology and specialty care in Latin America and other LMICs.
- 17 August 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessImplementation of an Integrated Electronic Health Record and Real-Time Dashboard System to Support Clinical Decision-Making in a Colombian Rheumatology Service
Background: Rheumatic diseases affect 10–20% of the global population and are a leading cause of disability. In Colombia, a limited rheumatology workforce and fragmented data systems hinder disease-burden monitoring, clinical decision-making, and resource planning. Electronic health records (EHR) integrated with real-time dashboards offer a scalable solution, yet their implementation in low- and middle-income countries (LMICs) remains scarce and underreported.Methods: We conducted a retrospective descriptive implementation study at the Rheumatology Department of Hospital de San José, Bogotá. Three data sources were integrated: administrative billing records, clinical EHR governed by Colombian Law 2015 of 2020, and a prospective REDCap research registry. Data from January 2020 to December 2023 underwent structured cleaning, deduplication, and consolidation into Google Sheets. SQL queries generated real-time visualizations through Looker Studio, enabling automated reporting of consultation volumes, demographics, ICD-10 diagnoses, and comorbidities. Implementation followed a multi-phase workflow with a multidisciplinary team of rheumatologists, epidemiologists, and data analysts.Findings: The dashboard captured 8,496 consultations from 4,698 unique patients over four years. Annual volumes rose from 1,130 in 2020 to a peak of 2,917 in 2022 (158% growth), declining slightly to 2,570 in 2023. Rheumatoid arthritis was the leading diagnosis (15.6%), followed by osteoarthritis (14.6%), fibromyalgia (11.8%), systemic lupus erythematosus (10.4%), Sjögren's syndrome (9.8%), and systemic sclerosis (4.7%), together accounting for 66.9% of diagnoses. Female patients comprised 82.3% of the cohort; polyautoimmunity was identified in 1.4%. The system reduced data fragmentation and enabled systematic longitudinal monitoring for the first time in this institution.Interpretation: Integrating freely available tools (REDCap and Looker Studio) can establish a functional, low-cost health information system in a resource-constrained LMIC setting. The resulting dashboard supported epidemiological monitoring for clinical management, resource planning, and research, and is scalable and replicable across rheumatology and specialty care in Latin America and other LMICs.
- Open Access
- 1 May 2025
- Published by AME Publishing Company in Translational Lung Cancer Research
- Vol. 14 (5) , 1756-1769
Deep learning in histopathology images for prediction of oncogenic driver molecular alterations in lung cancer: a systematic review and meta-analysis
Background: Lung cancer (LC) is the second most diagnosed cancer and the leading cause of cancer mortality worldwide. Non-small cell lung cancer (NSCLC) accounts for 85% of cases, with oncogenic alterations like EGFR, ALK, ROS1, and KRAS guiding targeted therapies. Their prevalence varies by ethnicity, smoking status, and gender. Advances in artificial intelligence (AI) enable molecular biomarker prediction from hematoxylin and eosin-stained whole-slide images (H&E WSIs), offering a non-invasive approach to precision oncology. This review assesses deep learning (DL) models predicting oncogenic drivers in NSCLC from H&E WSIs and their diagnostic accuracy. Methods: A systematic review registered in PROSPERO (CRD42024573602) was conducted in Embase, LILACS, Medline, Web of Science, and Cochrane to identify studies on DL models using H&E slides for LC gene alterations. Only English and Spanish studies were included. Key metrics were extracted for meta-analysis. Studies without LC-specific data, missing essential metrics, or with inconsistent results were excluded. Results: We found evidence that convolutional neural networks (CNNs) were the most common architectures in studies. Also, in the meta-analysis, ALK {sensitivity of 84% [95% confidence interval (CI): 62–95%] and specificity of 85% (95% CI: 55–96%)}, EGFR [80% (95% CI: 72–86%) and specificity of 77% (95% CI: 69–83%)] and TP53 [sensitivity and specificity of 70% (95% CI: 65–83%)] were the oncogenic driver molecular alterations that demonstrated the best predictive capability performance. Conclusions: Our results emphasize the potential of these models as screening tools despite H&E WSI.It is necessary to validate these predictive models among diverse populations and clinical outcomes. This approach is crucial and leaves an open door for advances in precision medicine, offering promising avenues for personalized treatment strategies.
- 1 May 2025
- Published by AME Publishing Company in Translational Lung Cancer Research
- Vol. 14 (5) , 1756-1769
Open AccessDeep learning in histopathology images for prediction of oncogenic driver molecular alterations in lung cancer: a systematic review and meta-analysis
Background: Lung cancer (LC) is the second most diagnosed cancer and the leading cause of cancer mortality worldwide. Non-small cell lung cancer (NSCLC) accounts for 85% of cases, with oncogenic alterations like EGFR, ALK, ROS1, and KRAS guiding targeted therapies. Their prevalence varies by ethnicity, smoking status, and gender. Advances in artificial intelligence (AI) enable molecular biomarker prediction from hematoxylin and eosin-stained whole-slide images (H&E WSIs), offering a non-invasive approach to precision oncology. This review assesses deep learning (DL) models predicting oncogenic drivers in NSCLC from H&E WSIs and their diagnostic accuracy. Methods: A systematic review registered in PROSPERO (CRD42024573602) was conducted in Embase, LILACS, Medline, Web of Science, and Cochrane to identify studies on DL models using H&E slides for LC gene alterations. Only English and Spanish studies were included. Key metrics were extracted for meta-analysis. Studies without LC-specific data, missing essential metrics, or with inconsistent results were excluded. Results: We found evidence that convolutional neural networks (CNNs) were the most common architectures in studies. Also, in the meta-analysis, ALK {sensitivity of 84% [95% confidence interval (CI): 62–95%] and specificity of 85% (95% CI: 55–96%)}, EGFR [80% (95% CI: 72–86%) and specificity of 77% (95% CI: 69–83%)] and TP53 [sensitivity and specificity of 70% (95% CI: 65–83%)] were the oncogenic driver molecular alterations that demonstrated the best predictive capability performance. Conclusions: Our results emphasize the potential of these models as screening tools despite H&E WSI.It is necessary to validate these predictive models among diverse populations and clinical outcomes. This approach is crucial and leaves an open door for advances in precision medicine, offering promising avenues for personalized treatment strategies.
- Open Access
- 1 April 2021
- Published by Elsevier in Revista Internacional de Acupuntura
- Vol. 15 (2) , 51-59
Revisión de ensayos clínicos y estudios de cohorte para el tratamiento de la migraña con acupuntura
- 1 April 2021
- Published by Elsevier in Revista Internacional de Acupuntura
- Vol. 15 (2) , 51-59
Open AccessRevisión de ensayos clínicos y estudios de cohorte para el tratamiento de la migraña con acupuntura
- 1 January 2021
- Published by Instituto de Altos Estudios Dr. Arnoldo Gabaldon in Boletín de Malariología y Salud Ambiental
- Vol. 61 (ee2) , 16-25
Estatinas y efectos pleiotrópicos en COVID-19: una revisión exploratoria
Introducción: La infección por SARS-COV-2 representa una grave emergencia de salud pública a nivel mundial; los adultos mayores comórbidos tienen una mayor riesgo de infección severa y mortalidad. Las enfermedades metabólicas y cardiovasculares se benefician de los tratamientos hipolipemiantes con estatinas, debido a sus efectos anti-inflamatorios, antioxidantes e incluso antivirales. Objetivo: Explorar la evidencia médica acerca de la eficacia y seguridad de las estatinas en el tratamiento de pacientes con COVID-19. Materiales y métodos: Revisión sistemática exploratoria en PubMed y Scopus, incluyendo publicaciones con datos empíricos (estudios observacionales y experimentales) en inglés y español. Además, se buscaron ensayos clínicos registrados en 17 registros primarios de la Red de Registros de la organización mundial de la salud. Resultados: Se incluyeron documentos (n=12) y registros de ensayos clínicos (n=10). Estudios de cohorte retrospectivos (n= 11) e in silico (n= 1). El país de origen de los autores en su mayoría fue Estados Unidos (n= 6). El 60% de los registros de ensayos clínicos se encuentran reclutando, la suma total de los participantes en los registros es de 14,204 pacientes. Conclusión: La evidencia presentada en esta revisión exploratoria sugiere que las estatinas, dados sus efectos pleiotrópicos, podrían tener un beneficio en el manejo de la COVID-19. Sin embargo, no es suficiente para generar una recomendación como parte del manejo estandarizado, requiriendo conocer los resultados de los ensayos clínicos aleatorizados en marcha.
- 1 January 2021
- Published by Instituto de Altos Estudios Dr. Arnoldo Gabaldon in Boletín de Malariología y Salud Ambiental
- Vol. 61 (ee2) , 16-25
Estatinas y efectos pleiotrópicos en COVID-19: una revisión exploratoria
Introducción: La infección por SARS-COV-2 representa una grave emergencia de salud pública a nivel mundial; los adultos mayores comórbidos tienen una mayor riesgo de infección severa y mortalidad. Las enfermedades metabólicas y cardiovasculares se benefician de los tratamientos hipolipemiantes con estatinas, debido a sus efectos anti-inflamatorios, antioxidantes e incluso antivirales. Objetivo: Explorar la evidencia médica acerca de la eficacia y seguridad de las estatinas en el tratamiento de pacientes con COVID-19. Materiales y métodos: Revisión sistemática exploratoria en PubMed y Scopus, incluyendo publicaciones con datos empíricos (estudios observacionales y experimentales) en inglés y español. Además, se buscaron ensayos clínicos registrados en 17 registros primarios de la Red de Registros de la organización mundial de la salud. Resultados: Se incluyeron documentos (n=12) y registros de ensayos clínicos (n=10). Estudios de cohorte retrospectivos (n= 11) e in silico (n= 1). El país de origen de los autores en su mayoría fue Estados Unidos (n= 6). El 60% de los registros de ensayos clínicos se encuentran reclutando, la suma total de los participantes en los registros es de 14,204 pacientes. Conclusión: La evidencia presentada en esta revisión exploratoria sugiere que las estatinas, dados sus efectos pleiotrópicos, podrían tener un beneficio en el manejo de la COVID-19. Sin embargo, no es suficiente para generar una recomendación como parte del manejo estandarizado, requiriendo conocer los resultados de los ensayos clínicos aleatorizados en marcha.